We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A California drugmaker has received a warning letter from the FDA for a direct-to-consumer TV ad and website that omitted or minimized risk information and made unsubstantiated effectiveness claims for an erectile dysfunction product.